Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006 Feb 18;332(7538):385-93.
doi: 10.1136/bmj.38731.532766.F6. Epub 2006 Feb 10.

Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis

Nina Buscemi  1 , Ben Vandermeer, Nicola Hooton, Rena Pandya, Lisa Tjosvold, Lisa Hartling, Sunita Vohra, Terry P Klassen, Glen Baker
Affiliations
Meta-Analysis

Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis

Nina Buscemi et al. BMJ. .

Abstract

Objective: To conduct a systematic review of the efficacy and safety of exogenous melatonin in managing secondary sleep disorders and sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder.

Data sources: 13 electronic databases and reference lists of relevant reviews and included studies; Associated Professional Sleep Society abstracts (1999 to 2003).

Study selection: The efficacy review included randomised controlled trials; the safety review included randomised and non-randomised controlled trials.

Quality assessment: Randomised controlled trials were assessed by using the Jadad Scale and criteria by Schulz et al, and non-randomised controlled trials by the Downs and Black checklist.

Data extraction and synthesis: One reviewer extracted data and another reviewer verified the data extracted. The inverse variance method was used to weight studies and the random effects model was used to analyse data.

Main results: Six randomised controlled trials with 97 participants showed no evidence that melatonin had an effect on sleep onset latency in people with secondary sleep disorders (weighted mean difference -13.2 (95% confidence interval -27.3 to 0.9) min). Nine randomised controlled trials with 427 participants showed no evidence that melatonin had an effect on sleep onset latency in people who had sleep disorders accompanying sleep restriction (-1.0 (-2.3 to 0.3) min). 17 randomised controlled trials with 651 participants showed no evidence of adverse effects of melatonin with short term use (three months or less).

Conclusions: There is no evidence that melatonin is effective in treating secondary sleep disorders or sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder. There is evidence that melatonin is safe with short term use.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Retrieval and selection of studies of exogenous melatonin in management of secondary sleep disorders and sleep disorders accompanying sleep restriction
Fig 2
Fig 2
Sleep onset latency in people with secondary sleep disorders
Fig 3
Fig 3
Sleep onset latency in people with sleep disorders accompanying sleep restriction
See this image and copyright information in PMC

Comment in

References

    1. National Institutes of Health. National Center on Sleep Disorders Research Plan. 2003. www.nhlbi.nih.gov/health/prof/sleep/res_plan/sleep-rplan.pdf (accessed 14 Jan 2006).
    1. Roller L. Treating sleep disorders. Austral J Pharm 2002;83: 443-7.
    1. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003;17: 273-85. - PubMed
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996;17: 1-12. - PubMed
    1. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273: 408-12. - PubMed

Publication types